Email Alert RSS
Volume 12 Issue 4
Jul.  2021
Turn off MathJax
Article Contents
Abstract
References
LIU Penghao, WANG Yuekun, LIAN Xin, HE Jialin, LIANG Naixin, LI Yongqiang, SI Xiaoyan, WANG Hanping, ZHANG Li, YOU Hui, CHENG Xin, ZHANG Xiaobo, ZHAO Dachun, MA Wenbin, WANG Yu. Five Times of MDT for a Patient with Brain Metastases of Renal Cell Carcinoma: A "Tailor-made" Pattern of Individualized Management[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 575-583. DOI: 10.12290/xhyxzz.20200210
Citation: LIU Penghao, WANG Yuekun, LIAN Xin, HE Jialin, LIANG Naixin, LI Yongqiang, SI Xiaoyan, WANG Hanping, ZHANG Li, YOU Hui, CHENG Xin, ZHANG Xiaobo, ZHAO Dachun, MA Wenbin, WANG Yu. Five Times of MDT for a Patient with Brain Metastases of Renal Cell Carcinoma: A "Tailor-made" Pattern of Individualized Management[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 575-583. DOI: 10.12290/xhyxzz.20200210
shu

Five Times of MDT for a Patient with Brain Metastases of Renal Cell Carcinoma: A "Tailor-made" Pattern of Individualized Management

  • 1.

    Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Department of Radiotherapy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 3.

    Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 4.

    Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 5.

    Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 6.

    Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 7.

    Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 8.

    Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

Fundamental Research Funds for the Central Universities 3332018029

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2016-I2M-2-001

Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program 2019ZLH101

More Information
  • Corresponding author:

    WANG Yu  Tel: 86-10-69152530, E-mail: ywang@pumch.cn

  • Received Date: August 04, 2020
  • Accepted Date: October 29, 2020
  • Available Online: June 06, 2021
  • Issue Publish Date: July 29, 2021
    Graphical Abstract
    • Abstract
  • Renal cell carcinoma(RCC) is a type of tumor with a high degree of malignancy in the urological system, often with distal metastases, especially to the central nervous system. These patients are often endowed with poorer prognosis and more complex management that require a multidisciplinary team(MDT). This article reported a case of clear cell renal cell carcinoma with multisystem metastases.The MDT of Peking Union Medical College Hospital(PUMCH) discussed and formulated the optimal individualized treatment scheme for the patient, and achieved good results after 5 consultations. Through a detailed analysis of discussions and decisions of MDT, the advantages in the treatment of such difficult and serious cases are demonstrated, including shortening the time window of treatment, breaking down departmental boundaries, improving patients' compliance, developing treatment recommendations in line with the concept of evidence-based medicine, and providing more accurate and individualized clinical managements for patients.
    • FullText(HTML)
    • References (26)
  • [1]
    NCCN. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 2[EB/OL ]. [2020-09-16]. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
    [2]
    NCCN. Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 2[EB/OL ]. [2020-09-16]. https://www.nccn.org/professionals/physician_gls/pdf/kidney_blocks.pdf.
    [3]
    Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors[J]. Cancer, 2008, 113: 5-21. DOI: 10.1002/cncr.23542
    [4]
    王彦卿, 陈野野, 黄诚, 等. 肺类癌的诊治进展[J]. 协和医学杂志, 2021, 12: 366-372. DOI: 10.3969/j.issn.1674-9081.2020.00.006

    Wang YQ, Cheng YY, Huang C, et al. Progress in the Diagnosis and Treatment of Pulmonary Carcinoids[J]. Xiehe Yixue Zazhi, 2021, 12: 366-372. DOI: 10.3969/j.issn.1674-9081.2020.00.006
    [5]
    Walts AE, Ines D, Marchevsky AM. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors[J]. Mod Pathol, 2012, 25: 1258-1264. DOI: 10.1038/modpathol.2012.81
    [6]
    沈松杰, 韩志军, 于双妮, 等. 乳腺癌合并恶性肺结节: 乳腺癌肺转移? 还是乳腺和肺双原发癌?[J]. 协和医学杂志, 2019, 11: 109-114. DOI: 10.3969/j.issn.1674-9081.20190116

    Shen SJ, Han ZJ, Yu SN, et al. Breast cancer combined with malignant pulmonary nodules: pulmonary metastases from breast cancer? or breast and lung metastases?[J]. Xiehe Yixue Zazhi, 2019, 11: 109-114. DOI: 10.3969/j.issn.1674-9081.20190116
    [7]
    Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30: 706-720. DOI: 10.1093/annonc/mdz056
    [8]
    Noronha V, Joshi A, Bakshi G, et al. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma[J]. Indian J Cancer, 2016, 53: 102-108. DOI: 10.4103/0019-509X.180824
    [9]
    Suarez-Sarmiento A Jr, Nguyen KA, Syed JS, et al. Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study[J]. Clin Genitourin Cancer, 2019, 17: e1163-e1170. DOI: 10.1016/j.clgc.2019.08.006
    [10]
    Bellesoeur A, Carton E, Alexandre J, et al. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy[J]. Drug Des Devel Ther, 2017, 11: 2801-2811. DOI: 10.2147/DDDT.S109640
    [11]
    Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14: 552-562. DOI: 10.1016/S1470-2045(13)70093-7
    [12]
    Kim YH, Kim JW, Chung HT, et al. Brain metastasis from renal cell carcinoma[J]. Prog Neurol Surg, 2012, 25: 163-175. DOI: 10.1159/000331190
    [13]
    Fokas E, Henzel M, Hamm K, et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients[J]. Strahlenther Onkol, 2010, 186: 210-217. DOI: 10.1007/s00066-010-2055-z
    [14]
    Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma[J]. Eur Urol, 2019, 75: 74-84. DOI: 10.1016/j.eururo.2018.08.036
    [15]
    Daugherty M, Daugherty E, Jacob J, et al. Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy[J]. Urol Oncol, 2019, 37: 182. e9-182. e15. DOI: 10.1016/j.urolonc.2018.10.021
    [16]
    de Sousa VML, Carvalho L. Heterogeneity in Lung Cancer[J]. Pathobiology, 2018, 85: 96-107. DOI: 10.1159/000487440
    [17]
    Sellner F. Isolated Pancreatic Metastases of Renal Cell Carcinoma-A Paradigm of a Seed and Soil Mechanism: A Literature Analysis of 1, 034 Observations[J]. Front Oncol, 2020, 10: 709. DOI: 10.3389/fonc.2020.00709
    [18]
    Turajlic S, Xu H, Litchfield K, et al. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal[J]. Cell, 2018, 173: 581-594. e12. DOI: 10.1016/j.cell.2018.03.057
    [19]
    Daboul N, Monga D, Bunker M. Primary renal carcinoid tumour with lung metastasis misdiagnosed as renal cell carcinoma[J]. BMJ Case Rep, 2016, 2016: bcr2015213432. http://www.ncbi.nlm.nih.gov/pubmed/26951438
    [20]
    Gill DM, Hahn AW, Hale P, et al. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma[J]. Curr Treat Options Oncol, 2018, 19: 6. DOI: 10.1007/s11864-018-0517-1
    [21]
    Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study[J]. Lancet Oncol, 2013, 14: 141-148. DOI: 10.1016/S1470-2045(12)70559-4
    [22]
    Escudier B, Motzer RJ, Tannir NM, et al. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214[J]. Eur Urol, 2020, 77: 449-453. DOI: 10.1016/j.eururo.2019.10.025
    [23]
    Lara P, Todd MB, Hamid O, et al. Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase Ⅰ/Ⅱ results from ECHO-202/KEYNOTE-037[J]. Clin Oncol, 2017, 35: 4515. http://www.researchgate.net/publication/345682256_Epacadostat_plus_pembrolizumab_in_patients_with_advanced_RCC_Preliminary_phase_III_results_from_ECHO-202KEYNOTE-037
    [24]
    Monteiro FSM, Soares A, Debiasi M, et al. First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis[J]. Clin Genitourin Cancer, 2020, 18: 244-251. e4. http://www.sciencedirect.com/science/article/pii/S155876732030046X
    [25]
    Siam L, Bleckmann A, Chaung HN, et al. The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study[J]. Oncotarget, 2015, 6: 29254-29267. DOI: 10.18632/oncotarget.4201
    [26]
    Suh JH, Kotecha R, Chao ST, et al. Current approaches to the management of brain metastases[J]. Nat Rev Clin Oncol, 2020, 17: 279-299. http://www.nature.com/articles/s41571-019-0320-3
    • Related Articles

  • Cited by

    Periodical cited type(2)

    1. 石易鑫，王月坤，邢昊，陈雯琳，刘德临，赵炳昊，阳天睿，牛佩，王裕，马文斌. 北京协和医院脑转移瘤多学科协作诊疗经验：159例病例总结. 协和医学杂志. 2023(02): 306-314 . 本站查看
    2. 任颖，唐飞龙，潘明. 儿童血液肿瘤疾病MDT模式在急性白血病合并感染中的应用. 齐齐哈尔医学院学报. 2023(06): 550-553 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (615) PDF downloads (74) Cited by(2)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close